Nicardipine for angina pectoris at rest and coronary arterial spasm.

The antiischemic effects and safety of nicardipine were assessed in 17 patients with angina at rest and coronary arterial spasm in a randomized placebo-controlled study over 8 to 13 weeks. Eleven patients had previously had unsatisfactory results with long-acting nitrates or other calcium blockers. The average daily dosage of nicardipine for optimal angina relief was 89 mg (range 40 to 160). During the double-blind phase, angina frequency decreased with nicardipine compared with placebo (mean 0.47 vs 2.11 attacks/day, p less than 0.05). A similar decrease in nitroglycerin requirements occurred (0.51 vs 2.77 tablets/day, p less than 0.05). During placebo periods, 51 episodes of ischemic ST-segment shifts occurred during 482 hours of ambulatory electrocardiographic monitoring and 12 (24%) were associated with angina. During nicardipine treatment, only 15 episodes of ST-segment shifts occurred during 498 hours of monitoring. In 1 patient a burning skin rash developed; otherwise, the drug was generally well tolerated. Thus, nicardipine is effective and safe in preventing symptomatic and asymptomatic ischemia in patients with coronary spasm. It may be particularly beneficial in patients with unsatisfactory responses to other therapy.

RCT Entities:   Population Interventions Outcomes